Global law firm White & Case LLP has advised Huvepharma on a €130 million credit facility.
“White & Case advised long-standing client Huvepharma on a deal that underlines our expertise in the efficient execution of debt finance transactions alongside the dedicated support of our clients in innovative projects in the healthcare and veterinary sectors,” said White & Case partner Jeremy Duffy, who led the Firm’s deal team.
The financing will be provided for significant research, development and innovation investments in the sphere of feed additives, veterinary pharmaceutical products and vaccines. Closing is expected to occur in late 2025 or early 2026.
Huvepharma is a fast-growing global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products.
The White & Case team that advised on the transaction was led by partner Jeremy Duffy (London) and included partners Guilhem Becvort (Luxembourg) and Grzegorz Abram (Warsaw), local partner Ruslana Hrischeva (Luxembourg), counsel Kevin Boyero (Paris) and associates Bernardo Zang, Scott Goldner, Jody Anderson, Christian Meijling (all London), Arnaud Marquet, Pierrick Romancant (both Luxembourg), Georgi Popov, Chloe Bouffard (both Paris), Maria Halasa, Joanna Misztal-Dzitko, Mateusz Dyduch (all Warsaw), Sara Ben Othmen and Maxim Arrazola de Oñate (both Brussels & Luxembourg).
Press contact
For more information please speak to your local media contact.
Read the orginal article: https://www.whitecase.com/news/press-release/white-case-advises-huvepharma-eu130-million-credit-facility
